Warfarin does not interfere with Lupus anticoagulant detection by dilute Russell's viper venom time

Horatiu Olteanu, Katharine A. Downes, Jigar Patel, Darja Praprotnik, Ravindra Sarode

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The dilute Russell's viper venom time (DRVVT) test is part of the diagnostic armamentarium used to detect lupus anticoagulant (LA). When testing patients on warfarin therapy, there is some concern of false positive results due to their low Factor X levels. We studied the diagnostic performance of the DRVVT ratio (DRVVT-R) to confirm the presence of LA in thrombophilia patients receiving warfarin therapy, and compared those results with a control group receiving warfarin for cardiac conditions but without thrombosis. Methods: The DRVVT (screen, confirm, and ratio), Factors II and X assays, and PT/INR were performed in patients receiving warfarin for thrombosis and in patients with cardiac conditions but no thrombosis (control group). Results: Patients on warfarin in the thrombosis group (n = 22) were positive for LA by DRVVT-R (ratio >1.27 was considered positive) whereas none of the patients in the control group (n=13) were positive for LA. The median DRVVT-R was significantly higher in the thrombosis group (1.60, range 1.29-1.92) as compared to controls (1.13, range 0.79-1.23, p<0.001) even though the INRs were comparable (median 2.3 for thrombosis group versus median of 2.2 for controls, p<0.05). Similarly, FX and FII levels were not significantly different in these two groups. Conclusions: We conclude that the use of the DRVVT-R allows for diagnosis of LA in patients receiving warfarin with therapeutic INR despite their decreased Factor X levels.

Original languageEnglish (US)
Pages (from-to)138-142
Number of pages5
JournalClinical Laboratory
Volume55
Issue number3-4
StatePublished - 2009

Fingerprint

Viper Venoms
Lupus Coagulation Inhibitor
Prothrombin Time
Warfarin
Thrombosis
Factor X
International Normalized Ratio
Control Groups
Prothrombin
Thrombophilia
Assays
Therapeutics
Testing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Warfarin does not interfere with Lupus anticoagulant detection by dilute Russell's viper venom time. / Olteanu, Horatiu; Downes, Katharine A.; Patel, Jigar; Praprotnik, Darja; Sarode, Ravindra.

In: Clinical Laboratory, Vol. 55, No. 3-4, 2009, p. 138-142.

Research output: Contribution to journalArticle

Olteanu, H, Downes, KA, Patel, J, Praprotnik, D & Sarode, R 2009, 'Warfarin does not interfere with Lupus anticoagulant detection by dilute Russell's viper venom time', Clinical Laboratory, vol. 55, no. 3-4, pp. 138-142.
Olteanu, Horatiu ; Downes, Katharine A. ; Patel, Jigar ; Praprotnik, Darja ; Sarode, Ravindra. / Warfarin does not interfere with Lupus anticoagulant detection by dilute Russell's viper venom time. In: Clinical Laboratory. 2009 ; Vol. 55, No. 3-4. pp. 138-142.
@article{498e87cfba4f439e9f4a20e357bc3f6a,
title = "Warfarin does not interfere with Lupus anticoagulant detection by dilute Russell's viper venom time",
abstract = "Background: The dilute Russell's viper venom time (DRVVT) test is part of the diagnostic armamentarium used to detect lupus anticoagulant (LA). When testing patients on warfarin therapy, there is some concern of false positive results due to their low Factor X levels. We studied the diagnostic performance of the DRVVT ratio (DRVVT-R) to confirm the presence of LA in thrombophilia patients receiving warfarin therapy, and compared those results with a control group receiving warfarin for cardiac conditions but without thrombosis. Methods: The DRVVT (screen, confirm, and ratio), Factors II and X assays, and PT/INR were performed in patients receiving warfarin for thrombosis and in patients with cardiac conditions but no thrombosis (control group). Results: Patients on warfarin in the thrombosis group (n = 22) were positive for LA by DRVVT-R (ratio >1.27 was considered positive) whereas none of the patients in the control group (n=13) were positive for LA. The median DRVVT-R was significantly higher in the thrombosis group (1.60, range 1.29-1.92) as compared to controls (1.13, range 0.79-1.23, p<0.001) even though the INRs were comparable (median 2.3 for thrombosis group versus median of 2.2 for controls, p<0.05). Similarly, FX and FII levels were not significantly different in these two groups. Conclusions: We conclude that the use of the DRVVT-R allows for diagnosis of LA in patients receiving warfarin with therapeutic INR despite their decreased Factor X levels.",
author = "Horatiu Olteanu and Downes, {Katharine A.} and Jigar Patel and Darja Praprotnik and Ravindra Sarode",
year = "2009",
language = "English (US)",
volume = "55",
pages = "138--142",
journal = "Clinical Laboratory",
issn = "1433-6510",
publisher = "Verlag Klinisches Labor GmbH",
number = "3-4",

}

TY - JOUR

T1 - Warfarin does not interfere with Lupus anticoagulant detection by dilute Russell's viper venom time

AU - Olteanu, Horatiu

AU - Downes, Katharine A.

AU - Patel, Jigar

AU - Praprotnik, Darja

AU - Sarode, Ravindra

PY - 2009

Y1 - 2009

N2 - Background: The dilute Russell's viper venom time (DRVVT) test is part of the diagnostic armamentarium used to detect lupus anticoagulant (LA). When testing patients on warfarin therapy, there is some concern of false positive results due to their low Factor X levels. We studied the diagnostic performance of the DRVVT ratio (DRVVT-R) to confirm the presence of LA in thrombophilia patients receiving warfarin therapy, and compared those results with a control group receiving warfarin for cardiac conditions but without thrombosis. Methods: The DRVVT (screen, confirm, and ratio), Factors II and X assays, and PT/INR were performed in patients receiving warfarin for thrombosis and in patients with cardiac conditions but no thrombosis (control group). Results: Patients on warfarin in the thrombosis group (n = 22) were positive for LA by DRVVT-R (ratio >1.27 was considered positive) whereas none of the patients in the control group (n=13) were positive for LA. The median DRVVT-R was significantly higher in the thrombosis group (1.60, range 1.29-1.92) as compared to controls (1.13, range 0.79-1.23, p<0.001) even though the INRs were comparable (median 2.3 for thrombosis group versus median of 2.2 for controls, p<0.05). Similarly, FX and FII levels were not significantly different in these two groups. Conclusions: We conclude that the use of the DRVVT-R allows for diagnosis of LA in patients receiving warfarin with therapeutic INR despite their decreased Factor X levels.

AB - Background: The dilute Russell's viper venom time (DRVVT) test is part of the diagnostic armamentarium used to detect lupus anticoagulant (LA). When testing patients on warfarin therapy, there is some concern of false positive results due to their low Factor X levels. We studied the diagnostic performance of the DRVVT ratio (DRVVT-R) to confirm the presence of LA in thrombophilia patients receiving warfarin therapy, and compared those results with a control group receiving warfarin for cardiac conditions but without thrombosis. Methods: The DRVVT (screen, confirm, and ratio), Factors II and X assays, and PT/INR were performed in patients receiving warfarin for thrombosis and in patients with cardiac conditions but no thrombosis (control group). Results: Patients on warfarin in the thrombosis group (n = 22) were positive for LA by DRVVT-R (ratio >1.27 was considered positive) whereas none of the patients in the control group (n=13) were positive for LA. The median DRVVT-R was significantly higher in the thrombosis group (1.60, range 1.29-1.92) as compared to controls (1.13, range 0.79-1.23, p<0.001) even though the INRs were comparable (median 2.3 for thrombosis group versus median of 2.2 for controls, p<0.05). Similarly, FX and FII levels were not significantly different in these two groups. Conclusions: We conclude that the use of the DRVVT-R allows for diagnosis of LA in patients receiving warfarin with therapeutic INR despite their decreased Factor X levels.

UR - http://www.scopus.com/inward/record.url?scp=65649124934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649124934&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 138

EP - 142

JO - Clinical Laboratory

JF - Clinical Laboratory

SN - 1433-6510

IS - 3-4

ER -